1 Min Read
Dec 22 (Reuters) - Oncology Venture Sweden Ab:
* IROFULVEN PHASE 2 CLINICAL STUDY APPLICATION APPROVED BY THE DANISH MEDICINES AGENCY AND THE ETHICS COMMITTEE Source text for Eikon: Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.